They should ban that author for an obvious pump and dump article. Tollovir is a mild anti-inflammatory it has not been shown to be a 3CL protease inhibitor. It's active ingredient is available across the counter at a much lower cost. There is no way Merck has any interest in TOMDF.

Like RLFTF and IPIX stay away unless you like to lose money.